Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344860 | 0.82 | STING1 (0.36) | CES2CES1LDHASTING1AKR1C3 | |
| SCHEMBL10564415 | 0.80 | CES2 (0.38) | CES2CES1AKR1C3AKR1C2MDM2 | |
| SCHEMBL606872 | 0.77 | TDP1 (0.49) | MEP1BCES2CES1TUBB1MAPT | |
| SCHEMBL1344665 | 0.77 | STING1 (0.36) | MEP1BTUBB1STING1AKR1C3AKR1C2 | |
| SCHEMBL27581775 | 0.76 | MEP1B (0.43) | MEP1BCES2CES1TUBB1HIF1A | |
| SCHEMBL27876515 | 0.75 | CES2 (0.48) | MEP1BCES2CES1 | |
| SCHEMBL116280 | 0.74 | CES2 (0.45) | MEP1BCES2CES1TUBB1MAPT | |
| SCHEMBL3573736 | 0.74 | TSHR (0.49) | MEP1BCES2CES1MAPTTDP1 | |
| SCHEMBL1345064 | 0.73 | CES2 (0.36) | CES2CES1AKR1C3AKR1C2TDP1 | |
| SCHEMBL24918 | 0.73 | CES2 (0.44) | MEP1BCES2CES1TUBB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | MEP1B 2142/4885CES2 1652/4885CES1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.